Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Total Debt (2016 - 2025)

Historic Total Debt for Myriad Genetics (MYGN) over the last 9 years, with Q3 2025 value amounting to $119.5 million.

  • Myriad Genetics' Total Debt rose 20641.03% to $119.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $119.5 million, marking a year-over-year increase of 20641.03%. This contributed to the annual value of $39.6 million for FY2024, which is 285.71% up from last year.
  • Per Myriad Genetics' latest filing, its Total Debt stood at $119.5 million for Q3 2025, which was up 20641.03% from $59.4 million recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' Total Debt registered a high of $119.5 million during Q3 2025, and its lowest value of $38.4 million during Q2 2023.
  • Its 4-year average for Total Debt is $55.8 million, with a median of $39.0 million in 2024.
  • Its Total Debt has fluctuated over the past 5 years, first soared by 325806.45% in 2021, then soared by 104.17% in 2024.
  • Quarter analysis of 4 years shows Myriad Genetics' Total Debt stood at $104.1 million in 2021, then crashed by 63.02% to $38.5 million in 2023, then grew by 2.86% to $39.6 million in 2024, then surged by 201.77% to $119.5 million in 2025.
  • Its last three reported values are $119.5 million in Q3 2025, $59.4 million for Q2 2025, and $59.3 million during Q1 2025.